A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice

A Multicenter, Prospective, Observational, Non-Interventional Study Evaluating the Efficacy and Safety of Using Tocilizumab (TCZ) for Confirmed Rheumatoid Arthritis (RA) Patients In Clinical Practice

This is a single-arm, open-label, non-randomized, multicenter trial to evaluate the efficacy and safety of using tocilizumab for confirmed rheumatoid arthritis participants in clinical practice.

Inclusion Criteria:

• Diagnosed with moderate-to-severe active rheumatoid arthritis (RA) for over 3 months
• Started on tocilizumab, with or without previous history of biological treatment

Exclusion Criteria:

• Pregnant or lactating women
• Treated with an investigational drug within 30 days prior to initiation of study drug
• Having a condition that, in the opinion of the investigator, could compromise the participant's safety or interfere with the study results